Sotatercept Clinical Trials
6 recruitingDrug
Phase 43Phase 22Phase 31
Showing 1–6 of 6 trials
Recruiting
Phase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC42 enrolled35 locationsNCT05587712
Recruiting
Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC815 enrolled93 locationsNCT07218029
Recruiting
Phase 4
Sotatercept in Pulmonary Arterial Hypertension
Pulmonary Artery Hypertension
University of Alberta27 enrolled1 locationNCT07140484
Recruiting
Phase 2
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Hypertension, Pulmonary
Merck Sharp & Dohme LLC130 enrolled56 locationsNCT06814145
Recruiting
Phase 4
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
Eisenmenger SyndromePulmonary Arterial Hypertension of Congenital Heart Disease
Kazuya Hosokawa36 enrolled10 locationsNCT07356778
Recruiting
Phase 4
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
Pulmonary Arterial HypertensionPulmonary Arterial Hypertension PAHPulmonary Arterial Hypertension WHO Group I
Amsterdam UMC, location VUmc20 enrolled1 locationNCT06658522